ANCA血管炎治療市場：按類型、藥物類型、分銷管道和地區分類

2026年ANCA血管炎治療市場規模估計為5.749億美元，預計2033年將達到8.363億美元。預計從2026年到2033年，該市場將以5.5%的複合年成長率成長。

嗜中性白血球球胞漿抗體（ANCA）相關性血管炎（AAV）是一組以微血管發炎和損傷為特徵的自體免疫疾病。發炎是由稱為ANCA的自身反應性抗體引起的，這些抗體與嗜中性白血球結合併過度激活它們。這種免疫系統功能障礙可能由遺傳或環境因素引起。 ANCA血管炎可引起多種症狀，取決於受累的器官和身體部位。例如，皮膚血管損傷可導致皮疹。腎臟血管問題會導致血液和蛋白質滲漏到尿液中，甚至造成腎臟損傷。 ANCA血管炎主要分為三種：顯微多發性血管炎（MPA）、肉芽腫性多血管炎（GPA）和嗜酸性粒細胞多血管炎（EGPA）。目前，該疾病尚無治癒方法，但有治療方法可以控制症狀。患者通常需要經歷兩個治療階段。第一種治療方法是誘導症狀緩解（誘導治療），第二種治療方法是盡可能長時間維持緩解狀態（維持治療）。

市場動態

市場主要企業正專注於研發活動，並致力於在各類醫學會議上展示其研究成果，預計這將推動預測期內的市場成長。例如，2022年5月，生物製藥公司ChemoCentryx宣布計畫在三場重要的醫學會議上發表報告。這些報告將涵蓋ADVOCATE III期臨床試驗的結果，該試驗證實了口服選擇性補體5a受體（C5aR）抑制劑Tavneos（avacopan）的核准，以及一項關於糖皮質激素在ANCA相關性血管炎中應用負擔的研究。這三場會議分別是：2022 年美國胸腔科協會年會（ATS 2022，2022 年 5 月 15 日至 17 日，舊金山）、2022 年國際藥物經濟學與結果研究學會年會（ISPOR 2022，2022 年 5 月 15 日至 18 日，華盛頓年會年 5 月 19 日至 22 日，法國巴黎/線上）。

本次調查的主要特點

• 本報告對全球 ANCA 血管炎治療市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模和復合年成長率（%）。
• 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本報告根據以下參數對全球 ANCA 血管炎治療市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
• 透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球 ANCA 血管炎治療市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 透過分析全球 ANCA 血管炎治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 法規環境
• PEST分析
• 流行病學
• 產品上市及核准

第4章 全球ANCA血管炎治療市場：按類型分類，2026-2033年

• 概述
• 肉芽腫性多血管炎（GPA）
• 顯微鏡下多血管炎（MPA）
• 嗜酸性粒細胞多血管炎（EGPA）
• 腎臟局限性血管炎

第5章 全球ANCA相關性血管炎治療市場：依藥物類型分類，2026-2033年

• 概述
• 糖皮質激素
• Cyclophosphamide
• Rituximab
• 胺基甲基葉酸
• Mycophenolate Mofetil
• Azathioprine
• 美泊利單抗
• 阿巴科潘
• 其他

第6章 全球ANCA血管炎治療市場：依通路分類，2026-2033年

• 概述
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球ANCA血管炎治療市場：依地區分類，2026-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第8章 競爭情勢

• ChemoCentryx, Inc.
• Vifor Pharma
• GlaxoSmithKline plc
• Amgen
• Genentech, Inc.
• Pfizer Inc.
• Biogen
• InflaRx GmbH
• AstraZeneca

第9章

• 調查方法
• 關於本公司

Anca Vasculitis Drug Market is estimated to be valued at USD 574.9 Mn in 2026 and is expected to reach USD 836.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).

Market Dynamics

Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual

Key features of the study

• This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ANCA vasculitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market

Market Segmentation

• Global ANCA Vasculitis Drug Market, By Type
  • Granulomatosis with Polyangiitis (GPA)
  • Microscopic Polyangiitis (MPA)
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Renal-limited Vasculitis
• Global ANCA Vasculitis Drug Market, By Drug Type
  • Glucocorticoids
  • Cyclophosphamide
  • Rituximab
  • Methotrexate
  • Mycophenolate mofetil
  • Azathioprine
  • Mepolizumab
  • Avacopan
  • Others
• Global ANCA Vasculitis Drug Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global ANCA Vasculitis Drug Market, By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • ChemoCentryx, Inc.
  • Vifor Pharma
  • GlaxoSmithKline plc
  • Amgen
  • Genentech, Inc.
  • Pfizer Inc.
  • Biogen
  • InflaRx GmbH
  • AstraZeneca.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Country
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• PEST Analysis
• Epidemiology
• Product Launch/Approvals

4. Global ANCA Vasculitis Drug Market, By Type, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Granulomatosis with Polyangiitis (GPA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Microscopic Polyangiitis (MPA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Renal-limited Vasculitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global ANCA Vasculitis Drug Market, By Drug Type, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Glucocorticoids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Cyclophosphamide
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Rituximab
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Methotrexate
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Mycophenolate mofetil
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Azathioprine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Mepolizumab
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Avacopan
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global ANCA Vasculitis Drug Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• ChemoCentryx, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vifor Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• InflaRx GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us